CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Ribavirin, PEG-Introndrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00299936
NCT00299936Phase 3Completed
CompareCT.gov

Comparison of PEG Interferon Alfa-2b Plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects

Weill Medical College of Cornell University·interventional·Posted Mar 7, 2006·Updated Mar 7, 2006

In Brief

A Phase 3 clinical trial evaluating Ribavirin, PEG-Intron for Chronic Hepatitis C. Completed.

Detailed Summary

The purpose of this study is to compare PEG-interferon alfa-2b and two different doses of rivavirin for the treatment of chronic hepatitis C in previously untreated adult subjects

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
Countries--
CollaboratorsSchering-Plough

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 7, 2006
TodayJul 2, 2026
Posted 20.3 years ago

Interventions

Ribavirin, PEG-Introndrug